The nation of Zimbabwe has rejected a substantial US health deal valued at $367m (£272m) over five years over the United States' request for sensitive biological samples.
This move became public following a official document from December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesman has since explained that the United States was demanding access to genetic material for scientific study and commercial gain but was not willing to guarantee the benefits from any future treatments.
"We are forced to start the challenging and unfortunate process of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for further dialogue to find a agreement suitable to both sides so the nation's vital HIV programme can be sustained.
Broader Context
This development comes after a comparable situation in neighbouring Kenya, where a court suspended a similar health funding agreement following concerns were filed about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had overseen aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to enhance openness and responsibility.
According to reports, 16 nations in Africa have so far agreed to similar agreements, representing over $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment via American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, with no equivalent promise of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," he stated.
"In essence, our nation would supply the raw materials for scientific discovery with no assurance that the final treatments would be available to our population if a new pandemic arise."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of bilateral health agreements were upending structures previously established via the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This system is designed to ensure that when a nation contributes its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," he added.
"We welcome further discussions with our American counterparts on how future collaboration might be arranged in a manner that respects the sovereignty and dignity of each country."
Health Experts Reaction
A leading public health body expressed it recognised the government's concerns, but recommended that negotiations need to persist given that much of the nation's HIV programmes relied on foreign aid.
"In cases where specific concerns exist, including those involving information security or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," the group commented.
The halted deal highlights the ongoing challenges between receiving vital foreign assistance and protecting a country's data in an ever more data-driven world.